Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain.
Pashna N MunshiShannon R McCurdyPublished in: American journal of hematology (2024)
Allogeneic hematopoietic cell transplantation (HCT) is no longer exclusively for the young. With an aging population, development of non-intensive remission-inducing strategies for hematologic malignancies, and novel graft-versus-host disease-prevention platforms, an older population of patients is pursuing HCT. The evolving population of HCT recipients requires an overhaul in the way we risk-stratify and optimize patients prior to HCT. Here, we review the history and current state of HCT for older adults and propose an assessment and intervention flow to bridge the gaps in today's clinical guidelines.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- randomized controlled trial
- stem cell transplantation
- physical activity
- bone marrow
- cell cycle arrest
- rheumatoid arthritis
- gold nanoparticles
- cell proliferation
- cell death
- patient reported outcomes
- clinical practice
- low dose
- disease activity
- high dose